SCHEMBL24419014

SCHEMBL24419014

COC(=O)Oc1ccc(Br)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.52
MAPT P10636 4/20 0.52
MEN1 O00255 4/20 0.52
LMNA P02545 3/20 0.52
MAPK1 P28482 1/20 0.52
RAB9A P51151 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
RXFP1 Q9HBX9 1/20 0.52
LDHA P00338 1/20 0.48
CYP1A2 P05177 1/20 0.48
MGLL Q99685 1/20 0.47
ALDH1A1 P00352 4/20 0.45
HSD17B10 Q99714 2/20 0.45
HTT P42858 1/20 0.45
KDM4E B2RXH2 2/20 0.44
HPGD P15428 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
MMP2 P08253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6228012 0.94 SLC6A3 (0.47) KMT2AMAPTMEN1LMNAMAPK1
SCHEMBL9337995 0.89 MAOB (0.53) KMT2AMAPTMEN1LMNAMAPK1
SCHEMBL676909 0.89 KMT2A (0.58) KMT2AMAPTMEN1LMNARAB9A
SCHEMBL57101 0.86 MEN1 (0.50) KMT2AMAPTMEN1LMNAMAPK1
SCHEMBL6936328 0.82 MMP2 (0.55) KMT2AMAPTMEN1LMNARAB9A
SCHEMBL8779173 0.82 KMT2A (0.52) KMT2AMAPTMEN1LMNARAB9A
SCHEMBL697317 0.82 CA1 (0.56) KMT2AMEN1LMNARAB9ACYP1A2
SCHEMBL13845221 0.82 MAPT (0.56) KMT2AMAPTMEN1LMNAMAPK1
SCHEMBL8830906 0.80 KMT2A (0.50) KMT2AMAPTMEN1LMNAALDH1A1
SCHEMBL1638842 0.80 MEN1 (0.45) KMT2AMAPTMEN1LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220142961-A1 CCL5 Inhibitors LAPKO INC, dba AFECTA PHARMACEUTICALS 2022-05-12 US disclosed
CN-112279770-A Chiral alpha-polysubstituted-alpha-fluorine-containing homoallylamine compound, and preparation method and application thereof 武汉大学 2021-01-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220142961-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 KMT2A 4842/4885MAPT 4264/4885MEN1 3749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.